Cited by 43Lipid metabolism and disordersLipoproteins and Cardiovascular HealthLipid metabolism and biosynthesis

Enhancement of preheparin serum lipoprotein lipase mass by bezafbirate administration

Totsuka, Mitsuya, Miyashita, Yoh, Ito, Yoshiaki, Watanabe, Hitoshi, Murano, Takeyoshi, Shirai, Kohji·2000·Atherosclerosis

Abstract

To clarify the clinical implication of preheparin serum lipoprotein lipase mass (preheparin LpL mass), we studied the relationships between preheparin LpL mass and serum lipids, including midband lipoproteins, which migrate between very low density lipoproteins and low density lipoproteins on polyacrylamide gel disc electrophoresis, in hyperlipidemias. And we also studied the changes of preheparin LpL mass in hypertriglyceridemic patients during bezafibrate administration, which is known to enhance LpL activity in postheparin plasma. Preheparin LpL mass correlated positively with high-density lipoprotein-cholesterol (HDL-C) (r=0.418, P<0.01) and negatively with triglyceride (TG) (r=-0.256, P<0.01), but did not correlate with total cholesterol (TC) in 64 hyperlipidemic (type IIa, IIb and IV) patients. The midband lipoproteins were observed in 80% of hypertriglyceridemic patients (32/40). Preheparin LpL mass in midband lipoprotein-positive subjects was lower significantly than that in midband-negative subjects. When bezafibrate (400 mg/day) was administrated to 40 hypertriglyceridemic patients for 4 months, TG level significantly decreased (-49+/-7%, P<0.01), TC levels decreased (-11+/-4%, not significant), and HDL-C levels increased (+27+/-4%, P<0.01). The midband lipoproteins disappeared in 95% of patients. Preheparin LpL mass significantly increased (+25+/-6%, P<0. 0005). In nine patients who stopped bezafibrate, TG levels significantly increased (+49+/-7%, P<0.01) and HDL-C levels decreased (-27+/-4%, P<0.01). Preheparin LPL mass significantly decreased (-25+/-6%, P<0.0005). These results suggested that bezafibrate administration enhanced preheparin LpL mass. And it might be implicated that enhanced LpL production by bezafibrate could reflect an increase of preheparin LpL mass.

Integrity signals

Registry

Crossref · 10.1016/s0021-9150(00)00394-4

Cites

23 of 23 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • 12 weeks of jogging training increased pre-heparin LPL concentrations in overweight men.

    “However, with several findings showing that pre-heparin LPL concentration indicate the amount of systemic LPL activity [64–66], Tanaka et al. turned the target to pre-heparin LPL, and found that 12 weeks of jogging training increased pre-heparin LPL concentrations in overweight men [67].”

    From Effects of aerobic exercise on lipids and lipoproteins (2017) · cites this paper as [67]

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Totsuka, M., Miyashita, Y., Ito, Y., Watanabe, H., Murano, T., & Shirai, K.
Affiliations
Toho University (JP)
Corresponding author
Shirai, Kohji
Venue
Atherosclerosis
Publisher
Elsevier BV
Published
2000-11
Volume
153
Issue
1
Pages
175-179
ISSN
0021-9150 (ISSN-L)
OpenAlex
W2094303805
Cited by
43
References
23
Citations by year
2025: 3 · 2021: 1 · 2018: 1 · 2017: 4 · 2016: 1 · 2015: 1 · 2014: 4
FWCI
1.49
Type
journal article
Language
en
Open access
closed
Locations
  • Atherosclerosis (publishedVersion)
  • PubMed (publishedVersion)
Funders
Kissei
Topics
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
  • Health Sciences › Medicine › Surgery › Lipoproteins and Cardiovascular Health
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Lipid metabolism and biosynthesis
Keywords
lipoprotein lipase, bezafibrate, hypertriglyceridemia, hyperlipidemia, HDL cholesterol, triglycerides, lipoprotein lipase activity, type II hyperlipoproteinemia, type IV hyperlipoproteinemia, drug withdrawal effects, serum lipids
MeSH terms
Hypolipidemic Agents, Bezafibrate, Drug Administration Schedule, Enzyme-Linked Immunosorbent Assay, Humans, Hyperlipidemias, Lipids, Lipoprotein Lipase, Lipoproteins, Electrophoresis, Gel, Two-Dimensional, Hypertriglyceridemia

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review